Todd Kinsella
Corporate Officer/Principal en Vividion Therapeutics, Inc. .
Perfil
Todd Kinsella is currently the Head-Biology at Vividion Therapeutics, Inc. He previously worked as Vice President-Research at Rigel Pharmaceuticals, Inc. Dr. Kinsella holds a doctorate degree from Stanford University and an undergraduate degree from the University of Arizona.
Cargos activos de Todd Kinsella
Empresas | Cargo | Inicio |
---|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2017 |
Antiguos cargos conocidos de Todd Kinsella.
Empresas | Cargo | Fin |
---|---|---|
RIGEL PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | - |
Formación de Todd Kinsella.
University of Arizona | Undergraduate Degree |
Stanford University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
RIGEL PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Bolsa de valores
- Insiders
- Todd Kinsella